Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 32.52 Billion KRW | 1.21% |
| 2022 | 29.81 Billion KRW | -4.69% |
| 2021 | 31.27 Billion KRW | 10.06% |
| 2020 | 28.41 Billion KRW | 8.61% |
| 2019 | 26.16 Billion KRW | -4.31% |
| 2018 | 27.34 Billion KRW | -7.78% |
| 2017 | 29.65 Billion KRW | 37.11% |
| 2016 | 21.62 Billion KRW | -14.9% |
| 2015 | 25.41 Billion KRW | 5.86% |
| 2014 | 24 Billion KRW | 19.14% |
| 2013 | 20.14 Billion KRW | 10.16% |
| 2012 | 18.29 Billion KRW | -8.96% |
| 2011 | 20.09 Billion KRW | -1.21% |
| 2010 | 20.33 Billion KRW | 13.67% |
| 2009 | 17.89 Billion KRW | 18.15% |
| 2008 | 15.14 Billion KRW | 3.16% |
| 2007 | 14.67 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 5.28 Billion KRW | -24.17% |
| 2024 Q2 | 6.97 Billion KRW | -16.15% |
| 2024 Q1 | 8.31 Billion KRW | 28.95% |
| 2023 FY | 30.17 Billion KRW | 1.21% |
| 2023 Q1 | 7.38 Billion KRW | 17.93% |
| 2023 Q4 | 6.45 Billion KRW | -17.13% |
| 2023 Q3 | 7.78 Billion KRW | -8.89% |
| 2023 Q2 | 8.54 Billion KRW | 15.62% |
| 2022 Q2 | 6.69 Billion KRW | -31.14% |
| 2022 Q1 | 9.71 Billion KRW | 125.72% |
| 2022 Q4 | 6.26 Billion KRW | -12.2% |
| 2022 Q3 | 7.13 Billion KRW | 6.67% |
| 2022 FY | 29.81 Billion KRW | -4.69% |
| 2021 Q3 | 7.28 Billion KRW | -4.35% |
| 2021 FY | 31.27 Billion KRW | 10.06% |
| 2021 Q1 | 12.07 Billion KRW | 67.97% |
| 2021 Q2 | 7.61 Billion KRW | -36.94% |
| 2021 Q4 | 4.3 Billion KRW | -40.9% |
| 2020 Q3 | 8.36 Billion KRW | 48.75% |
| 2020 Q2 | 5.62 Billion KRW | -22.33% |
| 2020 FY | 28.41 Billion KRW | 8.61% |
| 2020 Q1 | 7.24 Billion KRW | 76.75% |
| 2020 Q4 | 7.18 Billion KRW | -14.07% |
| 2019 Q4 | 4.09 Billion KRW | -35.95% |
| 2019 Q2 | 6.62 Billion KRW | -26.7% |
| 2019 Q1 | 9.04 Billion KRW | 60.2% |
| 2019 FY | 26.16 Billion KRW | -4.31% |
| 2019 Q3 | 6.39 Billion KRW | -3.51% |
| 2018 Q1 | 6.63 Billion KRW | 20.04% |
| 2018 FY | 27.34 Billion KRW | -7.78% |
| 2018 Q4 | 5.64 Billion KRW | -23.6% |
| 2018 Q3 | 7.38 Billion KRW | -3.71% |
| 2018 Q2 | 7.67 Billion KRW | 15.65% |
| 2017 Q4 | 5.52 Billion KRW | -19.02% |
| 2017 FY | 29.65 Billion KRW | 37.11% |
| 2017 Q2 | 8.21 Billion KRW | -9.53% |
| 2017 Q1 | 9.08 Billion KRW | 164.81% |
| 2017 Q3 | 6.82 Billion KRW | -16.91% |
| 2016 Q4 | 3.42 Billion KRW | -47.19% |
| 2016 Q3 | 6.49 Billion KRW | 8.01% |
| 2016 Q2 | 6.01 Billion KRW | 5.69% |
| 2016 Q1 | 5.68 Billion KRW | -10.53% |
| 2016 FY | 21.62 Billion KRW | -14.9% |
| 2015 Q4 | 6.35 Billion KRW | -22.52% |
| 2015 FY | 25.41 Billion KRW | 5.86% |
| 2015 Q2 | 7.18 Billion KRW | 96.6% |
| 2015 Q3 | 8.2 Billion KRW | 14.17% |
| 2015 Q1 | 3.65 Billion KRW | -35.87% |
| 2014 Q3 | 6.54 Billion KRW | 7.02% |
| 2014 FY | 24 Billion KRW | 19.14% |
| 2014 Q4 | 5.7 Billion KRW | -12.9% |
| 2014 Q2 | 6.11 Billion KRW | 8.49% |
| 2014 Q1 | 5.63 Billion KRW | 1.93% |
| 2013 Q2 | 5.3 Billion KRW | 22.66% |
| 2013 Q1 | 4.32 Billion KRW | -1.51% |
| 2013 FY | 20.14 Billion KRW | 10.16% |
| 2013 Q4 | 5.53 Billion KRW | 10.89% |
| 2013 Q3 | 4.98 Billion KRW | -5.94% |
| 2012 Q1 | 3.78 Billion KRW | -14.85% |
| 2012 Q2 | 5.05 Billion KRW | 33.6% |
| 2012 Q3 | 5.05 Billion KRW | -0.01% |
| 2012 FY | 18.29 Billion KRW | -8.96% |
| 2012 Q4 | 4.39 Billion KRW | -13.11% |
| 2011 FY | 20.09 Billion KRW | -1.21% |
| 2011 Q2 | 5.19 Billion KRW | -2.16% |
| 2011 Q4 | 4.44 Billion KRW | -15.08% |
| 2011 Q1 | 5.31 Billion KRW | 29.87% |
| 2011 Q3 | 5.23 Billion KRW | 0.65% |
| 2010 Q2 | 5.89 Billion KRW | 31.15% |
| 2010 FY | 20.33 Billion KRW | 13.67% |
| 2010 Q4 | 4.09 Billion KRW | -30.1% |
| 2010 Q3 | 5.85 Billion KRW | -0.78% |
| 2010 Q1 | 4.49 Billion KRW | 14.96% |
| 2009 Q1 | 4.5 Billion KRW | 51.52% |
| 2009 FY | 17.89 Billion KRW | 18.15% |
| 2009 Q3 | 5.89 Billion KRW | 72.09% |
| 2009 Q2 | 3.42 Billion KRW | -23.84% |
| 2009 Q4 | 3.91 Billion KRW | -33.69% |
| 2008 FY | 15.14 Billion KRW | 3.16% |
| 2008 Q1 | 5.48 Billion KRW | 85.19% |
| 2008 Q2 | 3.3 Billion KRW | -39.69% |
| 2008 Q3 | 3.37 Billion KRW | 2.08% |
| 2008 Q4 | 2.97 Billion KRW | -12.05% |
| 2007 Q4 | 2.96 Billion KRW | -32.92% |
| 2007 Q1 | 3.75 Billion KRW | 0.0% |
| 2007 Q2 | 3.4 Billion KRW | -9.48% |
| 2007 FY | 14.67 Billion KRW | 0.0% |
| 2007 Q3 | 4.41 Billion KRW | 29.77% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8822.302% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 57.695% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 140.88% |
| HANDOK Inc. | 12.57 Billion KRW | -158.57% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1735.132% |
| Yuhan Corporation | 74.56 Billion KRW | 56.379% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -190.962% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 280.269% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 85.537% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -964.282% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -126.649% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -5353.546% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -3274.795% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -20.323% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8822.302% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 519.351% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -706.348% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 146.497% |
| JW Holdings Corporation | 143.66 Billion KRW | 77.361% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 160.888% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 86.811% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 67.573% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 168.629% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -369.546% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -402.627% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -272.508% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8822.302% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 33.306% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 75.62% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 67.573% |
| Yuhan Corporation | 74.56 Billion KRW | 56.379% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -55.472% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -943.343% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 24.351% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 67.573% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -58.78% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 40.809% |
| CKD Bio Corp. | -20.15 Billion KRW | 261.395% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -0.907% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -28.547% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 168.629% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 1.876% |
| Boryung Corporation | 68.26 Billion KRW | 52.356% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 186.741% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -126.649% |
| JW Lifescience Corporation | 32.09 Billion KRW | -1.351% |